A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...
Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...
Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from acute myeloid leukemia (AML) for residual disease before receiving a bone marrow ...
A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukaemia (AML) by helping doctors identify if they might relapse up to three ...
Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers ...
A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research (NIHR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results